If you need to report an Adverse Event or Product Complaint or you cannot find a product please contact 1-800-LILLYRX (1-800-545-5979)

Please provide us with the following information so that we can verify your identity as you move through the process of submitting a medical question. By providing your information we can ensure your question is triaged appropriately and a response can be provided to you in timely manner.

Product * Product Adcirca (tadalafil) tablets Alimta (pemetrexed) for injection Amyvid (Florbetapir F18) injection Bamlanivimab and Etesevimab together Baqsimi (glucagon) nasal powder Baricitinib Basaglar (insulin glargine) injection Cialis (tadalafil) tablets Cyramza (ramucirumab) injection Effient (prasugrel) tablets Emgality (galcanezumab-gnlm) injection Erbitux (cetuximab) injection for intravenous infusion Forteo (teriparatide injection) Glucagon for injection (rDNA origin) Humalog Therapies Humatrope (somatropin [rDNA origin]) Humulin Therapies Luxura HD (Luxura HD) injection Lyumjev (insulin lispro - aabc) injection Non-branded insulins Olumiant (baricitinib) tablets Portrazza (necitumumab) injection Retevmo (selpercatinib) capsules Reyvow (lasmiditan) tablets CV Rezvoglar (insulin glargine-aglr) injection Taltz (ixekizumab) injection Tauvid (flortaucipir F18 injection) Trulicity (dulaglutide) injection Verzenio (abemaciclib) tablets Ang2 Antibody (LY3127804) Aurora Kinase Inhibitor CSF-1R Antibody (LY3022855) CXCR4 Peptide Antagonist (LY2510924) Donanemab Emibetuzumab ERK Inhibitor (LY3214996) FGFR Inhibitor (LY2874455) Galunisertib Lebrikizumab Pirtobrutinib (LOXO-305) Merestinib Mirikizumab Notch Inhibitor (LY3039478) PD-L1 Antibody (LY3300054) Pegilodecakin PI3K/mTOR Dual Inhibitor (LY3023414) Prexasertib Ralimetinib SERD (LY3484356) Sintilimab Solanezumab TGF-Beta Receptor 1 Inhibitor (LY3200882) TIM-3 Antibody Tirzepatide Non Product

Your Question *

Title

First Name *

Last Name *

Type of HCP * Please Select Nurse Physician Pharmacist Other

Contact By *

Email

Telephone

Mailing Address

Fields with (*) are mandatory

For more information about Lilly's privacy practice, please view the Privacy Statement.

Submit

---